Diabetes and Obesity Drugs Show Surprising Promise in Treating Addiction, Major Study Finds

A groundbreaking study has found that medications commonly prescribed for type 2 diabetes and obesity may offer significant benefits in preventing and treating addictions to multiple substances. The research, published in the British Medical Journal and led by researchers at Washington University School of Medicine in the United States, analysed data on nearly two million individuals and found that people taking GLP-1 receptor agonist drugs showed substantially reduced risks across a range of addictive behaviours.

GLP-1 medications—such as semaglutide and tirzepatide—have become well-known in recent years for their effectiveness in weight management. These drugs work by mimicking glucagon-like peptide-1, a hormone that regulates blood sugar and appetite. However, the latest evidence suggests their benefits may extend far beyond weight loss and metabolic control.

The research examined two groups. Among people without existing substance use disorders, those prescribed GLP-1 drugs showed a 14 to 25 per cent reduced risk of developing addictions to alcohol, cannabis, cocaine, nicotine, or opioids over a three-year follow-up period, compared to people prescribed alternative diabetes medications (SGLT2 inhibitors, which work differently in the body).

The reduction was particularly striking for opioid addiction, representing one of the most significant findings given the ongoing global opioid crisis. For patients who already had substance use disorders, the benefits were even more pronounced. GLP-1 users experienced a 29 per cent reduction in emergency department visits, 26 per cent fewer hospitalisations related to their addiction, 39 per cent fewer overdose events, and a 50 per cent reduction in drug-related deaths.

These figures represent potentially life-saving outcomes and suggest that GLP-1 medications could address a critical gap in addiction medicine.

The mechanism behind these benefits involves how GLP-1 drugs interact with the brain’s reward system. Both addictive substances and unhealthy eating patterns activate the mesolimbic system—a region of the brain associated with reward and reinforcement. When people develop obesity or substance use disorders, their brains become conditioned to crave these rewarding stimuli.

GLP-1 medications suppress the reward signals in this brain region, reducing cravings and what many patients describe as “reward noise.” This same mechanism that helps people manage their appetite may also reduce cravings for addictive substances including nicotine, alcohol, opioids, and stimulants.

Lead researcher Dr Ziyad Al-Aly highlighted an important distinction: “The biggest revelation is that these drugs work across different substances. Previously in addiction medicine, medications were tailored to treat specific substances—nicotine patches for smoking, other treatments for alcohol, and different treatments for opioids. There is no precedent for a medicine with this property of working across addictive substances.”

This finding is significant because it suggests the potential for establishing GLP-1 medications as an entirely new class of drugs that could both prevent and treat multiple types of addiction simultaneously. This could revolutionise addiction treatment, particularly given that many individuals struggle with multiple substance use disorders simultaneously.

However, researchers emphasise that more studies are needed to fully understand how these medications should be used for addiction treatment. The current research does not provide detailed information about optimal dosing or duration of treatment for addiction purposes, and questions remain about what happens when patients stop taking the medications.

It is important to note that whilst the evidence is promising, GLP-1 medications are not currently approved by UK regulatory authorities specifically for treating addiction. Current approvals cover type 2 diabetes and weight management. Furthermore, these medications are not a substitute for psychological support, behavioural therapy, and comprehensive addiction treatment programmes.

The study was observational in nature, which means it can show associations but cannot definitively prove causation. Additionally, the research was conducted on US veterans, and results may not be identical across different populations. More rigorous randomised controlled trials will be necessary before these drugs could be routinely prescribed for addiction treatment in the NHS.

Key Takeaways

• A large US study found GLP-1 medications reduced addiction risk by 14–25 per cent across multiple substances
• In patients already with substance use disorders, GLP-1 use was associated with 39 per cent fewer overdoses and 50 per cent fewer drug-related deaths
• These drugs work by suppressing reward signals in the brain that reinforce addictive cravings
• Further research is needed before these medications could be approved specifically for addiction treatment in the UK

What This Means for Kent Residents

For people across Kent struggling with addiction, this research offers hope that new treatment options may become available in future. Whilst GLP-1 medications are not currently prescribed by the NHS for addiction treatment, the findings could influence how healthcare professionals approach complex cases where patients have both metabolic conditions and substance use disorders.

If you or someone you know is struggling with addiction, support is available through the NHS. Kent and Medway NHS Trust provides specialist substance use services, and your GP can provide referrals to local addiction treatment services. Additionally, the FRANK helpline (a national service) provides free, confidential advice about drugs and drugs-related issues.